Cipla Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Cipla Ltd filed with BSE on 27 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Cipla reported its highest ever Q1 revenue of INR7,119 crores, up 2% year-on-year as reported, with growth adjusted for an accounting presentation change at around 4%. The One India business grew 12% year-on-year with chronic portfolio strength, while North America delivered quarterly revenue of $162 million with the launch of generic Ventolin during the quarter. EBITDA margin excluding other income stood at 16.7%, and management attributed the compression to launch-related investments, one-time inventory charges, and war-related cost impact.
Numbers mentioned
Revenue: INR7,100 crores (Q1 FY27)
p. 3
“I'm delighted to share that we have delivered the highest ever Q1 revenue with revenues of INR7,100 crores in this Q1.”
Achin Gupta, page 3 of the filed PDF · View the filing
Revenue: INR7,119 crores (Q1 FY27)
p. 5
“We reported a quarterly revenue of INR7,119 crores with a 2% growth Y-o-Y.”
Ashish Adukia, page 5 of the filed PDF · View the filing
One India business growth: 12% Y-o-Y (Q1 FY27)
p. 3
“Our One India business achieved its highest ever quarterly revenue with 12% Y-o-Y growth, reflecting a strong performance across key therapies and underscoring the strength of our franchise in the IPM.”
Achin Gupta, page 3 of the filed PDF · View the filing
Branded prescription business growth: 15.4% (Q1 FY27)
p. 3
“Within this, the branded prescription business continued to witness strong momentum across chronic portfolio, delivering a market-leading growth of 15.4% during the quarter as per IQVIA data.”
Achin Gupta, page 3 of the filed PDF · View the filing
Chronic mix: 60.4% (Q1 FY27)
p. 4
“Our overall chronic mix strengthened this quarter to 60.4% Y-o-Y.”
Achin Gupta, page 4 of the filed PDF · View the filing
North America revenue: 162 million (Q1 FY27)
p. 4
“In North America, we delivered quarterly revenue of 162 million.”
Achin Gupta, page 4 of the filed PDF · View the filing
US Albuterol MDI market share: 21%
p. 4
“Cipla continues to hold the number 1 position in the overall U.S. Albuterol MDI market this quarter with our market share standing at 21% as per IQVIA data for the week ending June 2026.”
Achin Gupta, page 4 of the filed PDF · View the filing
South Africa private market secondary growth: 6.5%
p. 5
“In the private market, we achieved strong secondary growth of 6.5%, outperforming the overall market growth of 5.7% as per IQVIA MAT data.”
Achin Gupta, page 5 of the filed PDF · View the filing
EMEU growth: 5% Y-o-Y in USD terms
p. 5
“In EMEU, we continued the growth trajectory with a 5% Y-o-Y growth in USD terms.”
Achin Gupta, page 5 of the filed PDF · View the filing
EBITDA margin excluding other income: 16.7% (Q1 FY27)
p. 5
“The EBITDA margin, excluding the other income, stood at 16.7% for the quarter.”
Ashish Adukia, page 5 of the filed PDF · View the filing
Gross margin: 62.5% (Q1 FY27)
p. 5
“The reported gross margin after material cost stood at 62.5%.”
Ashish Adukia, page 5 of the filed PDF · View the filing
Total expense: INR3,260 crores (Q1 FY27)
p. 6
“The total expense for the quarter stood at INR3,260 crores, reflecting an 8.3% increase over the previous quarter.”
Ashish Adukia, page 6 of the filed PDF · View the filing
R&D investment: INR486 crores, 6.8% of revenue (Q1 FY27)
p. 6
“R&D investments for the quarter were INR486 crores or 6.8% of revenue, directed largely towards the product filing and key development programs.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Profit after tax: INR789 crores, 11% of sales (Q1 FY27)
p. 6
“Profit after tax for the quarter stood at INR789 crores, representing 11% of sales and ETR for the quarter stood at 27%.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Debt: INR600 crores (as of 30 June 2026)
p. 6
“As of 30 June, 2026, the debt on our balance sheet, including lease liabilities, stood at INR600 crores with net cash equivalent balance at INR9,494 crores, and this was after the dividend payment that we made this quarter of INR1,050 crores.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Yurpeak revenue: approximately INR80 crores (Q1 FY27)
p. 7
“And within that, as per IQVIA, approximately INR80 crores was from Yurpeak, right.”
Achin Gupta, page 7 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
North America exit run rate — $1 billion · FY27 exit
stated conditionally by Achin Gupta
p. 8
“So, there are other peptides and other products, which are in the approval queue, but we've been highlighting the three respi and the one peptide, which are more significant of the backlog. So, yes, and that is the approval of these will give us a line of sight towards that $1 billion exit rate.”
Achin Gupta, page 8 of the filed PDF · View the filing
EBITDA margin — 18.5% to 20% · FY27
stated conditionally by Ashish Adukia
p. 16
“No, I think, see, our effort for the year is to focus on new launches and with the approvals coming through based on that, we have budgeted our internal estimates this 18.5% to 20% is based on a plan.”
Ashish Adukia, page 16 of the filed PDF · View the filing
North America business growth — FY27
stated conditionally by Achin Gupta
p. 5
“Looking ahead, we expect North America business to continue its sequential growth trajectory during the year supported by the upcoming product launches and continued commercial execution.”
Achin Gupta, page 5 of the filed PDF · View the filing
EMEU margin
stated as an aspiration by Ashish Adukia
p. 6
“In EMEU, the top priority is to drive top-line growth while maintaining a strong margin trajectory.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Chronic mix in India — next 2-3 years
stated as an aspiration by Achin Gupta
p. 17
“So, we've looked at it strategically. So, you would see that improvement over the coming 2, 3 years in terms of larger share coming from chronic.”
Achin Gupta, page 17 of the filed PDF · View the filing
War-related cost impact — 1% to 2% of revenue
stated conditionally by Ashish Adukia
p. 9
“But if you could assume about 1% to 2% of revenue in that kind of a range for the overall cost impact due to war.”
Ashish Adukia, page 9 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Ashish said adjusted growth would be around 4% versus reported 2%, with the impact largely on South Africa.
Answered by Ashish Adukia
Asked by Saion Mukharji: How did the accounting presentation change impact reported growth rates, and can it be quantified for India and South Africa?
p. 6
“Sure. So, see, I think if you go through the note, Saion, you'll find the numbers mentioned out there for the previous Y-o-Y quarter as well. So, you'll be able to calculate the growth and the growth would be somewhere around 4% if you just adjust for the previous year number as well.”
Ashish Adukia, page 6 of the filed PDF · View the filing
Achin confirmed the three respiratory launches plus one large peptide remain the significant ones underpinning the exit rate target.
Answered by Achin Gupta
Asked by Damayanti Kerai: Is the $1 billion U.S. exit run rate guidance for FY27 still maintained given only three respiratory launches and one peptide instead of four peptides mentioned earlier?
p. 8
“So, there are other peptides and other products, which are in the approval queue, but we've been highlighting the three respi and the one peptide, which are more significant of the backlog.”
Achin Gupta, page 8 of the filed PDF · View the filing
Ashish declined to quantify it precisely, saying it was slightly higher than normalized write-offs.
Answered by Ashish Adukia
Asked by Vishal Manchanda: Can you quantify the inventory write-off impact on gross margins this quarter?
p. 9
“I’m not quantifying this. So, this all sits as part of COGS and amongst other provisionings that we take.”
Ashish Adukia, page 9 of the filed PDF · View the filing
Ashish confirmed the tender loss impact would continue in coming quarters while private market growth remains strong.
Answered by Ashish Adukia
Asked by Bino Pathiparampil: Will the South Africa tender loss continue to depress reported revenue for the coming quarters?
p. 10
“So, Yes, you will see continuing impact of tender in South Africa.”
Ashish Adukia, page 10 of the filed PDF · View the filing
Ashish explained the low margin reflects upfront costs for new launches not yet generating revenue, plus temporary war-related costs, and expects gradual improvement.
Answered by Ashish Adukia
Asked by Vivek Agrawal: Why has EBITDA margin fallen below pre-Revlimid levels, and where is the company bleeding margin?
p. 18
“The reason why it is low is multiple things, which we've been talking about. One, a lot of the operating expenses to launch these new products have already been committed, right?”
Ashish Adukia, page 18 of the filed PDF · View the filing
Achin said it would not be possible to put a floor, but the company is aiming for its stated guidance range.
Answered by Achin Gupta
Asked by Foram Parekh: Is there a threshold EBITDA margin level below which the business cannot fall if new launches are delayed?
p. 17
“I think it won't be kind of possible for us to put a floor. We are aiming for that ballpark and that page is where we are aiming for, and that's where we would expect to drive the business.”
Achin Gupta, page 17 of the filed PDF · View the filing
Risks flagged
War-related cost impact on gross margins
p. 9
“But if you could assume about 1% to 2% of revenue in that kind of a range for the overall cost impact due to war.”
Ashish Adukia, page 9 of the filed PDF · View the filing
Loss of a South Africa tender continuing to impact revenue
p. 7
“So that is one of the impact that is there. And on the private market, there has been a growth.”
Ashish Adukia, page 7 of the filed PDF · View the filing
One Form 483 observation at InvaGen New York facility following FDA inspection
p. 5
“during this month, the U.S. FDA concluded a routine GMP inspection at Invagen facility in New York, which included with one Form 483 observation, which we are committed to addressing within the stipulated time line.”
Achin Gupta, page 5 of the filed PDF · View the filing
Advair facing increased competition reducing its revenue opportunity
p. 15
“No. I think that one has three or four competitors now. So, that won't be $100 million.”
Achin Gupta, page 15 of the filed PDF · View the filing
Higher than normal one-time inventory write-off charges
p. 9
“So, there has been a little higher than a normalized that we budget for, and that is why I called it out that there is a one-time, kind of, an inventory charge that is there.”
Ashish Adukia, page 9 of the filed PDF · View the filing
Timing uncertainty on Lanreotide resumption due to regulatory approval dependence
p. 16
“I think timing is a little bit fluid because both have dependence on the regulatory approvals.”
Achin Gupta, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.